BSX — Boston Scientific Share Price
Last trade - 00:00- $122.74bn
- $130.64bn
- $14.24bn
- 93
- 14
- 98
- 77
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 31.44 | ||
| PEG Ratio (f) | 1.55 | ||
| EPS Growth (f) | 25.36% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.03 | ||
| Price to Tang. Book | 220.37 | ||
| Price to Free Cashflow | 66.64 | ||
| Price to Sales | 8.06 | ||
| EV to EBITDA | 33.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.45% | ||
| Return on Equity | 9.48% | ||
| Operating Margin | 17.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10,735 | 9,913 | 11,888 | 12,682 | 14,240 | 16,277.04 | 18,046.67 | 7.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -14.68 | -60.5 | +163.18 | +9.91 | +3.07 | +91.24 | +13.59 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
Directors
- Michael Mahoney CHM
- Daniel Brennan CFO (56)
- Arthur Butcher EVP
- Joseph Fitzgerald EVP (57)
- Edward Mackey EVP (58)
- Ian Meredith EVP (64)
- Jeffrey Mirviss EVP (55)
- David Pierce EVP (57)
- Eric Thepaut EVP (59)
- Jodi Eddy SVP
- Desiree Rallsmorrison SVP (55)
- Wendy Carruthers SVP (52)
- Maulik Nanavaty SVP (59)
- Scott Olson SVP
- Meghan Scanlon SVP (48)
- John Sorenson SVP (53)
- Edward Ludwig LED (69)
- David Wichmann DRC (58)
- Nelda Connors IND
- Charles Dockendorff IND (67)
- Yoshiaki Fujimori IND (70)
- Donna James IND (63)
- David Roux IND (64)
- John Sununu IND (56)
- Ellen Zane IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 22nd, 1979
- Public Since
- May 19th, 1992
- No. of Shareholders
- 5,432
- No. of Employees
- 48,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 1,472,626,135
- Address
- 300 Boston Scientific Way, MARLBOROUGH, 01752-1291
- Web
- https://www.bostonscientific.com/en-US/Home.html
- Phone
- +1 5086834000
- Auditors
- Ernst & Young LLP
Latest News for BSX
Upcoming Events for BSX
Q3 2024 Boston Scientific Corp Earnings Release
Q4 2024 Boston Scientific Corp Earnings Release
Similar to BSX
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
As of Today at 19:40 UTC, shares in Boston Scientific are trading at $83.35. This share price information is delayed by 15 minutes.
Shares in Boston Scientific last closed at $83.35 and the price had moved by +56.17% over the past 365 days. In terms of relative price strength the Boston Scientific share price has outperformed the S&P500 Index by +16.71% over the past year.
The overall consensus recommendation for Boston Scientific is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBoston Scientific does not currently pay a dividend.
Boston Scientific does not currently pay a dividend.
Boston Scientific does not currently pay a dividend.
To buy shares in Boston Scientific you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $83.35, shares in Boston Scientific had a market capitalisation of $122.74bn.
Here are the trading details for Boston Scientific:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BSX
Based on an overall assessment of its quality, value and momentum Boston Scientific is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Boston Scientific is $87.94. That is 5.51% above the last closing price of $83.35.
Analysts covering Boston Scientific currently have a consensus Earnings Per Share (EPS) forecast of $2.41 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Boston Scientific. Over the past six months, its share price has outperformed the S&P500 Index by +11.21%.
As of the last closing price of $83.35, shares in Boston Scientific were trading +17.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Boston Scientific PE ratio based on its reported earnings over the past 12 months is 31.44. The shares last closed at $83.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Boston Scientific's management team is headed by:
- Michael Mahoney - CHM
- Daniel Brennan - CFO
- Arthur Butcher - EVP
- Joseph Fitzgerald - EVP
- Edward Mackey - EVP
- Ian Meredith - EVP
- Jeffrey Mirviss - EVP
- David Pierce - EVP
- Eric Thepaut - EVP
- Jodi Eddy - SVP
- Desiree Rallsmorrison - SVP
- Wendy Carruthers - SVP
- Maulik Nanavaty - SVP
- Scott Olson - SVP
- Meghan Scanlon - SVP
- John Sorenson - SVP
- Edward Ludwig - LED
- David Wichmann - DRC
- Nelda Connors - IND
- Charles Dockendorff - IND
- Yoshiaki Fujimori - IND
- Donna James - IND
- David Roux - IND
- John Sununu - IND
- Ellen Zane - IND